We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Low-Cost, Simple-to-Use, Ultrafast Point-of-Care COVID-19 Test to Provide RT PCR Results in 8 Minutes

By LabMedica International staff writers
Posted on 09 Oct 2020
A new low-cost, simple-to-use, ultrafast point-of-care test for COVID-19 aims to provide reverse transcription polymerase chain reaction (RT PCR) results in just eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

The promising new COVID-19 rapid-testing technology platform has been developed by Rover Diagnostics (New York, NY, USA) and Columbia Engineering (New York, NY, USA). More...
Rover’s ultrafast, portable PCR technology is based on two breakthroughs in science and engineering and it meets all the conditions for successful point-of-care PCR. First, it uses microfluidic sample preparation developed by Prof. Sam Sia’s lab at Columbia University’s Dept. of Bioengineering. This technology allows Rover to eliminate expensive, complex sample prep equipment in favor of a small, disposable chip.

Secondly, the platform uses a new approach to thermal cycling that bypasses the standard Peltier device which requires 40-60 minutes for amplification. Instead of radiant heat coming from outside the vial or well, the platform use photothermal gold nanoparticles to generate heat from inside. The result is thermal cycling that is 10x faster and uses 100x less energy than is possible today. Rover aims to combine these two technologies into an easy-to-use, sample-to-answer instrument. Furthermore, Rover will integrate HIPAA-compliant cloud access to allow for instant notification and large-scale data analysis. Rover’s COVID-19 rapid-testing technology platform has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies.

“We were determined to develop a testing platform for all kinds of viruses that is cheap, reliable, and accessible to everyone,” said Sia, an innovator in point-of-care blood tests, wearable sensors, and implantable devices. “With Rover, we can now perform thermal cycling, which is the backbone of high-performing DNA and RNA testing, several times faster.”

“We are expanding our testing of clinical samples and bringing together additional resources and expertise to finalize the design and speed to manufacturing. The NIH RADx initiative is accelerating our progress to bring the fast PCR platform to the widest possible good,” added Sia.

Related Links:
Rover Diagnostics
Columbia Engineering



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.